Dominant negative mutations in the C-propeptide of COL2A1 cause platyspondylic lethal skeletal dysplasia, torrance type, and define a novel subfamily within the type 2 collagenopathies
- 10 January 2005
- journal article
- research article
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 133A (1) , 61-67
Abstract
Platyspondylic lethal skeletal dysplasia (PLSD) Torrance type (PLSD‐T) is a rare skeletal dysplasia characterized by platyspondyly, brachydactyly, and metaphyseal changes. Generally a perinatally lethal disease, a few long‐term survivors have been reported. Recently, mutations in the carboxy‐propeptide of type II collagen have been identified in two patients with PLSD‐T, indicating that PLSD‐T is a type 2 collagen‐associated disorder. We studied eight additional cases of PLSD‐T and found that all had mutations in the C‐propeptide domain of COL2A1. The mutational spectrum includes missense, stop codon and frameshift mutations. All non‐sense mutations were located in the last exon, where they would escape non‐sense‐mediated RNA‐decay. We conclude that PLSD‐T is caused by mutations in the C‐propeptide domain of COL2A1, which lead to biosynthesis of an altered collagen chain (as opposed to a null allele). Similar mutations have recently been found to be the cause of spondyloperipheral dysplasia, a non‐lethal dominant disorder whose clinical and radiographical features overlap those of the rare long‐term survivors with PLSD‐T. Thus, spondyloperipheral dysplasia and PLSD‐T constitute a novel subfamily within the type II collagenopathies, associated with specific mutations in the C‐propeptide domain and characterized by distinctive radiological features including metaphyseal changes and brachydactyly that set them apart from other type 2 collagenopathies associated with mutations in the triple‐helical domain of COL2A1. The specific phenotype of C‐propeptide mutations could result from a combination of diminished collagen fibril formation, toxic effects through the accumulation of unfolded collagen chains inside the chondrocytes, and alteration of a putative signaling function of the carboxy‐propeptide of type 2 collagen.Keywords
Funding Information
- European Skeletal Dysplasia Network (ESDN) (QLGI-CT2001-02188 (EU grant number))
- Swiss Federal Office for Science and Education (Grant BBW) (01.258)
- Swiss National Science Foundation (3100A0-100485)
This publication has 17 references indexed in Scilit:
- Spondyloperipheral dysplasia is caused by truncating mutations in the C‐propeptide of COL2A1American Journal of Medical Genetics Part A, 2004
- Identification of COL2A1 mutations in platyspondylic skeletal dysplasia, Torrance typeJournal of Medical Genetics, 2004
- Missense Mutations in the Homeodomain of HOXD13 Are Associated with Brachydactyly Types D and EThe American Journal of Human Genetics, 2003
- Vitreoretinopathy with phalangeal epiphyseal dysplasia, a type II collagenopathy resulting from a novel mutation in the C-propeptide region of the moleculeJournal of Medical Genetics, 2002
- A single amino acid substitution (D1441Y) in the carboxyl-terminal propeptide of the proα1(I) chain of type I collagen results in a lethal variant of osteogenesis imperfecta with features of dense bone diseasesJournal of Medical Genetics, 2002
- Report of five novel and one recurrentCOL2A1 mutations with analysis of genotype-phenotype correlation in patients with a lethal type II collagen disorderJournal of Medical Genetics, 2000
- Growth Arrest and Spontaneous Differentiation Are Initiated Through an Autocrine Loop in Clonally Derived Schwann Cells by α1‐Procollagen I C‐PropeptideJournal of Neurochemistry, 1999
- A specific collagen type II gene (COL2A1) mutation presenting as spondyloperipheral dysplasiaAmerican Journal of Medical Genetics, 1996
- Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3Nature Genetics, 1995
- Further heterogeneity within lethal neonatal short-limbed dwarfism: The platyspondylic typesThe Journal of Pediatrics, 1979